Home Tags ADCT-402

Tag: ADCT-402

Featured Image: ADC Therapeutics Booth at AACR 2018 Courtesy: © 2017 – 2018. Sunvalley Communication, LLC / Evan Wendt. Used with permission.

Freenome Enters Biomarker Development Collaboration with ADC Therapeutics

Swiss-based ADC Therapeutics, an oncology-drug development company specializes in the development of antibody drug conjugates (ADCs), and Freenome, a biotech company pioneering the a...

SOPHiA Genetics and ADC Therapeutics Partner for Biomarker Discovery in Pivotal...

ADC Therapeutics and SOPHiA GENETICS have entered into a collaboration to identify genomic markers associated with clinical response to loncastuximab tesirine (ADCT-402), an antibody...

15th ICML: Loncastuximab Tesirine Shows Significant Activity in R/R Diffuse Large...

Loncastuximab tesirine (ADCT‐402), an anti‐CD19 antibody‐drug conjugate (ADC) conjugated via a protease cleavable linker to SG3199, a highly cytotoxic DNA minor groove interstrand cross-linking...
Featured Image: View of Lugano old town with mountains in the background, Switzerland. Courtesy: © 2017. Fotolia. Used with permission.

Pyrrolobenzodiazepine-based ADCs Demonstrate Potential in R/R Lymphomas

The International Conference on Malignant Lymphoma (ICML) has, since its first edition in 1981, become one of the must-attend conferences for the scientific community...
Featured Image: ADC Therapeutics Booth at AACR 2018 Courtesy: © 2017 – 2018. Sunvalley Communication, LLC / Evan Wendt. Used with permission.

First DLBCL Patient Dosed in Trial with Loncastuximab Tesirine

Swiss-base ADC Therapeutics, an oncology drug discovery and development company specializing in the development of proprietary antibody-drug conjugates (ADCs) targeting hematological malignancies and solid...

First Clinical Data from ADCT-402 Demonstrates Encouraging Antitumor Activity in r/r...

The first clinical data from an ongoing Phase I clinical trial evaluating ADCT-402 for the treatment of relapsed or refractory non-Hodgkin’s lymphoma has been...

Successful Funding Round Expected to Accelerate ADC Therapeutics’ Clinical Development

Swiss Biotech company ADC Therapeutics, an oncology drug discovery and development company specializing in the development of proprietary antibody-drug conjugates or ADCs for the treatment...

First Patient Dosed in Phase I Trial of ADCT-402 in CD-19...

Late last week, Swiss based ADC Therapeutics, an oncology drug development company that specializes in the development of proprietary antibody-drug conjugates (ADCs) targeting major...

FEATURED RESOURCES